Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505008 | 1.00 | LMNA (0.44) | LMNAL3MBTL1SMN1; SMN2GAACA1 | |
| SCHEMBL4844487 | 0.82 | KMT2A (0.50) | LMNAL3MBTL1SMN1; SMN2GAACA1 | |
| SCHEMBL23319841 | 0.79 | ALDH1A1 (0.58) | LMNAL3MBTL1SMN1; SMN2GAACA1 | |
| SCHEMBL7151344 | 0.76 | LMNA (0.49) | LMNAL3MBTL1SMN1; SMN2GAACA1 | |
| SCHEMBL3219444 | 0.74 | LMNA (0.59) | LMNAL3MBTL1SMN1; SMN2GAACA1 | |
| SCHEMBL22718193 | 0.74 | CA1 (0.40) | LMNAL3MBTL1SMN1; SMN2GAACA1 | |
| SCHEMBL22612213 | 0.73 | CA1 (0.61) | LMNAL3MBTL1SMN1; SMN2GAACA1 | |
| SCHEMBL20767241 | 0.73 | CA1 (0.63) | LMNAL3MBTL1SMN1; SMN2GAACA1 | |
| SCHEMBL6933412 | 0.73 | GAA (0.63) | LMNAL3MBTL1SMN1; SMN2GAACA1 | |
| SCHEMBL879053 | 0.73 | CA1 (0.61) | LMNAL3MBTL1SMN1; SMN2GAACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-11458149-B1 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-10-04 | — | — | US | disclosed |
| CN-114502540-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3976192-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | LMNA 2907/4885L3MBTL1 3224/4885SMN1; SMN2 3736/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | LMNA 2907/4885L3MBTL1 3224/4885SMN1; SMN2 3736/4885 |
| US-11458149-B1 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | LMNA 2907/4885L3MBTL1 3224/4885SMN1; SMN2 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.